CJC-1295

  • CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the anterior pituitary gland to release endogenous growth hormone (GH). The Drug Affinity Complex (DAC) extends the half-life of the peptide, allowing for longer-lasting GH secretion and providing a sustained increase in GH levels without promoting excessive production. This results in enhanced tissue repair, fat loss, muscle growth, and anti-aging effects.

    • Increased Growth Hormone Secretion: Stimulates the release of growth hormone (GH), leading to various metabolic and regenerative effects.

    • Improved Muscle Growth: Enhances lean muscle mass development by increasing GH and IGF-1 (Insulin-Like Growth Factor 1) production.

    • Fat Loss: Promotes lipolysis (fat breakdown) and reduces body fat, especially in combination with exercise.

    • Improved Recovery: Accelerates recovery from injuries and workouts by enhancing protein synthesis and tissue repair.

    • Enhanced Sleep Quality: Improves deep sleep and recovery during rest, which is associated with increased GH release during sleep.

    • Improved Skin Elasticity: Promotes collagen production, leading to better skin health and reduced signs of aging.

    • Increased Bone Density: Enhances bone strength and mineral density, making it beneficial for osteoporosis prevention.

    • Improved Cognitive Function: Supports brain function and may contribute to neuroprotection and cognitive enhancement.

    • Boosted Immune Function: Enhances the immune response by promoting tissue repair and cellular regeneration.

    • Long-lasting Effects: Compared to other GH-releasing peptides, CJC-1295 has a longer half-life, leading to sustained GH release over time.

    • Growth Hormone Deficiency: Treats conditions related to insufficient GH levels, such as muscle wasting and decreased bone density.

    • Muscle Wasting Disorders: Used to promote muscle growth in conditions involving muscle wasting, like HIV or cancer cachexia.

    • Anti-Aging Therapy: Applied in anti-aging protocols due to its ability to enhance collagen production, skin elasticity, and GH levels.

    • Obesity: Assists in weight loss by stimulating fat breakdown and reducing body fat.

    • Athletic Performance: Enhances muscle growth, fat loss, and recovery, making it popular among athletes and bodybuilders.

    • Injury Recovery: Promotes faster healing of muscles, tendons, and ligaments after injury or surgery.

    • Osteoporosis: Increases bone mineral density, reducing the risk of fractures and bone loss in aging populations.

    • Metabolic Syndrome: Improves insulin sensitivity and reduces visceral fat, supporting metabolic health.

    • Chronic Fatigue Syndrome: May improve energy levels and reduce fatigue by enhancing recovery and tissue repair.

    • Skin Rejuvenation: Used in cosmetic medicine to improve skin health and appearance by boosting collagen levels.

    • Teichman SL, Neale A, Lawrence B, et al. "CJC-1295, a Long-Acting Analog of GHRH, Enhances Growth Hormone Secretion in Humans." Journal of Clinical Endocrinology & Metabolism. 2006; 91(3): 799-805.

    •  Junnila RK, List EO, Berryman DE, et al. "The GH/IGF-1 Axis in Obesity: Pathophysiology and Therapeutic Considerations." Nature Reviews Endocrinology. 2013; 9(6): 346-356.

    •  Cervellin G, Lippi G. "Acromegaly: A Focus on Clinical Diagnostic Aspects." Annals of Clinical Biochemistry. 2012; 49(1): 202-215.

    •  Caliebe J, Brodski V, Blankenstein O, et al. "Growth Hormone Secretion in Short Children Born Small for Gestational Age." European Journal of Endocrinology. 2010; 162(3): 569-575.

    •  Chapman IM. "Nutritional Disorders: Aging, Growth Hormone and Physical Performance." Growth Hormone & IGF Research. 2000; 10(Suppl B): S49-S55.

    •  O’Sullivan AJ, Kelly JJ, Hoffman DM, et al. "Body Composition and Energy Metabolism in Acromegaly." Journal of Clinical Endocrinology & Metabolism. 1994; 78(2): 381-386.

    •  Veldhuis JD, Roemmich JN, Richmond EJ, et al. "Endocrine Control of Body Composition in Infancy, Childhood, and Puberty." Endocrine Reviews. 2005; 26(1): 114-146.

    •  Liu H, Bravata DM, Olkin I, et al. "Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly." Annals of Internal Medicine. 2007; 146(2): 104-115.

    •  Carroll PV, Christ ER, Bengtsson BA, et al. "Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review." Journal of Clinical Endocrinology & Metabolism. 1998; 83(2): 382-395.

    •  Clemmons DR. "Metabolic Actions of Growth Hormone in Adults: A Review." Growth Hormone & IGF Research. 2012; 22(5): 96-100.